{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"The Proportion of participants with reported ICANS as defined by the American Society for Transplantation and Cellular Therapy (ASTCT) will be reported","groups":[{"description":"Participants received pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Pembrolizumab)"}],"populationDescription":"Data not collected","reportingStatus":"POSTED","timeFrame":"Up to 30 days after discontinuing study treatment, approximately 1 year and 8 months","title":"Proportion of Participants With Immune-effector Cell-associated Neurotoxicity Syndrome (ICANS)","type":"SECONDARY"}